History
Documents created during the development process.
Background information
-
-
Appendix A - Decision paper presented to the Institute's Guidance Executive
-
Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 112 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 529 KB)
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Novartis Ranibizumab TA155
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Novartis Ranibizumab TA155
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: DSU Ranibizumab TA155
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: DSU Ranibizumab TA155
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: DSU Ranibizumab TA155 (PDF 64 KB)
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal panel decision
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal panel decision
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal panel decision (PDF 68 KB)
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appeal announcement information
-
Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Derbyshire County PCT
-
Derbyshire County PCT: appeal received
-
-
Derbyshire County PCT: initial scrutiny letter
-
-
Derbyshire County PCT: response to scrutiny letter
-
Derbyshire County PCT: response to scrutiny letter (PDF 211 KB)
-
Derbyshire County PCT: final scrutiny letter
-
-
Macular degeneration (age-related) - pegaptanib and ranizumab: appeal from Pfizer
-
Pfizer: appeal received
-
-
Pfizer: initial scrutiny letter
-
-
Pfizer: response to scrutiny letter
-
-
Pfizer: final scrutiny letter
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: notice of appeal
Macular degeneration (age-related)- pegaptanib and ranibizumab: final appraisal determination
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Final appraisal determination
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to public comments on the first Appraisal Consultation Document
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee and commentator comments on the first Appraisal Consultation Document
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to public comments on the second Appraisal Consultation Document
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Response to consultee and commentator comments on the second Appraisal Consultation Document
-
-
Macular degeneration (age-related)- pegaptanib and ranibizumab: Consultee and commentator comments on the ACD
-
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (confidential information removed)
-
Lucentis dose capping pharmacy dispensing form
-
-
Lucentis dose capping pharmacy claim form
-
-
The Lucentis dose capping scheme flow diagram
-
-
Appendix 1 - Dose capping scheme summary proposal to NICE
-
Appendix 1 - Dose capping scheme summary proposal to NICE (PDF 21 KB)
-
Novartis comment
-
-
Consultee and commentator comments on the ACD: Welsh Assembly Government
-
Consultee and commentator comments on the ACD: Welsh Assembly Government (PDF 32 KB)
-
Consultee and commentator comments on the ACD: NHS Quality Improvement Scotland
-
Consultee and commentator comments on the ACD: NHS Quality Improvement Scotland (PDF 24 KB)
-
Consultee and commentator comments on the ACD: Derbyshire County Primary Care Trust
-
Consultee and commentator comments on the ACD: Derbyshire County Primary Care Trust (PDF 28 KB)
-
Consultee and commentator comments on the ACD: Department of Health, Social Services and Public Safety for Northern Ireland
-
-
Consultee and commentator comments on the ACD: Department of Health
-
Consultee and commentator comments on the ACD: Department of Health (PDF 34 KB)
-
Consultee and commentator comments on the ACD: Joint comment from Royal National Institute of the Blind and Macular Disease Society
-
-
Consultee and commentator comments on the ACD: Royal College of Ophthalmologists
-
Consultee and commentator comments on the ACD: Royal College of Ophthalmologists (PDF 29 KB)
-
Consultee and commentator comments on the ACD: Royal College of Nursing
-
Consultee and commentator comments on the ACD: Royal College of Nursing (PDF 25 KB)
-
Consultee and commentator comments on the ACD: Pfizer Limited
-
Consultee and commentator comments on the ACD: Pfizer Limited (PDF 91 KB)
-
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited
-
Consultee and commentator comments on the ACD: Novartis Pharmaceuticals Limited (PDF 542 KB)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Expert comments on the ACD
-
Expert comments on the ACD: Mr Simon Harding
-
-
Expert comments on the ACD: Mrs Jennifer Nosek
-
-
Expert comments on the ACD: Professor Andrew Lotery
-
Expert comments on the ACD: Professor Andrew Lotery (PDF 28 KB)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Report on public comments received on the Appraisal Consultation Document (ACD)
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Additional scenario analysis undertaken by the Assessment Group, Southampton Health Technology Assessment Centre (SHTAC) related to consultation on first ACD
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Additional scenario analysis undertaken by the Decision Support Unit related to consultation on first ACD
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 2 (December 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 2 (December 2007)
-
-
Evaluation report (December 2007)
-
Further analysis requested by NICE in response to consultation on the ACD
-
Ranibizumab and Pegaptanib for Age related Macular Degeneration: Report by the NICE Decision Support Unit
-
-
Additional analysis commissioned by the NHS R&D HTA Programme on behalf of NICE: Further analysis requested by NICE in response to consultation on the ACD - Addendum
-
-
Additional analysis commissioned by the NHS R&D HTA Programme on behalf of NICE: Further analysis requested by NICE in response to consultation on the ACD
-
-
Consultee and Commentator comments on the further analysis requested by NICE in response to consultation on the ACD
-
Consultee and Commentator comments: External Experts
-
Nosek
-
-
Lotery
-
-
Harding
-
-
Consultee and Commentator comments: Other Consultees
-
Derbyshire County PCT
-
-
NHS Quality Improvement Scotland
-
-
Consultee and Commentator comments: Professional and Patient Groups
-
Macular Disease Society and Royal National Institute for the Blind
-
Macular Disease Society and Royal National Institute for the Blind (PDF 52 KB)
-
Royal College of Nursing
-
-
Royal College of Ophthalmologists, the Macular Disease Society and the Royal National Institute of Blind People
-
-
Royal College of Ophthalmologists, the Macular Disease Society and the Royal National Institute of Blind People 2
-
-
Consultee and Commentator comments: Manufacturer/Sponsor
-
Pfizer Ltd
-
-
Novartis Pharmaceuticals UK
-
-
First Appraisal Consultation document as issued to consultees
-
First Appraisal Consultation document (as issued to consultees)
-
First Appraisal Consultation document (as issued to consultees) (PDF 112 KB)
-
Consultee and commentator comments on the first Appraisal Consultation
-
Consultee and commentator comments on the first Appraisal Consultation: External experts
-
Willie - 2nd comment
-
-
Willie
-
-
Nosek
-
-
Lotery
-
-
Harding
-
-
Consultee and commentator comments on the first Appraisal Consultation: Commentators
-
NHS Quality Improvement Scotland
-
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Department of Health, Social Services and Public Safety for Northern Ireland (PDF 31 KB)
-
Consultee and commentator comments on the first Appraisal Consultation: Other Consultees
-
Welsh Assembly Government
-
-
Heywood Middleton and Rochdale PCT
-
-
Department of Health
-
-
Consultee and commentator comments on the first Appraisal Consultation: Professional and patient groups
-
Royal National Institute of the Blind and Macular Disease Society
-
Royal National Institute of the Blind and Macular Disease Society (PDF 78 KB)
-
Royal College of Ophthalmologists - Appendix 4
-
-
Royal College of Ophthalmologists - Appendix 3
-
-
Royal College of Ophthalmologists - Appendix 2
-
-
Royal College of Ophthalmologists - Appendix 1
-
-
Royal College of Ophthalmologists - Covering letter
-
Royal College of Ophthalmologists - Covering letter (PDF 62 KB)
-
Royal College of Ophthalmologists - part 2
-
-
Royal College of Ophthalmologists - part 1
-
-
Royal College of Nursing
-
-
Age Concern England
-
-
Consultee and commentator comments on the first Appraisal Consultation: Manufacturer / Sponsor
-
Pfizer Ltd
-
-
Novartis Pharmaceuticals UK
-
-
Comments from website consultation
-
-
Report to the Appraisal Committee summarising patient and public comments on the first Appraisal consultation
-
Report summarising patient and public comments - Appendix 4
-
Report summarising patient and public comments - Appendix 4 (PDF 6.37 MB)
-
Report summarising patient and public comments - Appendix 2
-
Report summarising patient and public comments - Appendix 2 (PDF 280 KB)
-
Report summarising patient and public comments - Appendix 1
-
Report summarising patient and public comments - Appendix 1 (PDF 1.08 MB)
-
Report summarising patient and public comments
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation document (Large print format) (December 2007)
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation document (Audio version) (December 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Introduction and timetable
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 1. Appraisal committee
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 2. Clinical Needs
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 3. Technologies
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Appendix B
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: Appendix A
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 8. Proposed date for review of guidance
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 7. Related NICE guidance
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 6. Proposed recommendations for further research
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 5. Implementation
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab - ACD 2 - Audio version: 4. Clinical Effectiveness
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation document (original PDF format) (December 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 1 (June 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: appraisal consultation 1 (June 2007)
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation information
-
Evaluation report
-
Overview
-
-
Macular degeneration (age-related) - ranibizumab and pegaptanib: assessment report
-
Macular degeneration (age-related) - ranibizumab and pegaptanib: assessment report (PDF 1.87 MB)
-
Consultee and commentator comments on the assessment report
-
NHS Quality Improvement Scotland
-
-
Novartis
-
-
Pfizer
-
-
Royal College of Nurses
-
-
Royal College of Opthamologists
-
-
Royal Institute for the Blind and Macular Disease Society
-
Royal Institute for the Blind and Macular Disease Society (PDF 32 KB)
-
Non-manufacturer submission
-
Macular Disease Society
-
-
Royal College of Nursing
-
-
Royal College of Opthamologists
-
-
Manufacturer submissions (executive summary only)
-
Novartis Pharmaceuticals UK Ltd
-
-
Pfizer
-
-
Expert written personal statements
-
Lotery
-
-
McLaughlin
-
-
Nosek
-
-
Harding
-
-
Willie
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (large print format)
-
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Introduction and timetable
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appraisal committee's recommendations
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Clinical need and practice
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - The technologies
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - The evidence
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Implementation
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Proposed recommendations for further research
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Related NICE guidance
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Proposed date for review guidance
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix A - Appraisal committee members
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix B - Sources of evidence considered by the committee
-
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: Appraisal consultation (audio version) - Appendix C - Commenting on the consultation document
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final protocol
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final protocol
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final protocol (PDF 101 KB)
Macular degeneration (age-related) - pegaptanib and ranibizumab: final scope
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final scope
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final scope (PDF 39 KB)
Macular degeneration (age-related) - pegaptanib and ranibizumab: final matrix
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final matrix
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: final matrix (PDF 40 KB)
Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the draft scope
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the draft scope
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the provisional matrix
-
Macular degeneration (age-related) - pegaptanib and ranibizumab: summary of consultee and commentator comments on the provisional matrix
-